JP2005506340A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005506340A5 JP2005506340A5 JP2003535542A JP2003535542A JP2005506340A5 JP 2005506340 A5 JP2005506340 A5 JP 2005506340A5 JP 2003535542 A JP2003535542 A JP 2003535542A JP 2003535542 A JP2003535542 A JP 2003535542A JP 2005506340 A5 JP2005506340 A5 JP 2005506340A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- targeted therapeutic
- igf
- amino acids
- targeted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32965001P | 2001-10-16 | 2001-10-16 | |
| US10/136,841 US7396811B2 (en) | 2001-04-30 | 2002-04-30 | Subcellular targeting of therapeutic proteins |
| US10/136,639 US20030072761A1 (en) | 2001-10-16 | 2002-04-30 | Methods and compositions for targeting proteins across the blood brain barrier |
| US38445202P | 2002-05-29 | 2002-05-29 | |
| US38601902P | 2002-06-05 | 2002-06-05 | |
| US40881602P | 2002-09-06 | 2002-09-06 | |
| PCT/US2002/032968 WO2003032727A1 (en) | 2001-10-16 | 2002-10-16 | Methods and compositions for targeting underglycosylated proteins across the blood brain barrier |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009143436A Division JP2009203241A (ja) | 2001-10-16 | 2009-06-16 | 血液脳関門をわたる過小グリコシル化タンパク質の標的化のための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005506340A JP2005506340A (ja) | 2005-03-03 |
| JP2005506340A5 true JP2005506340A5 (enExample) | 2006-01-12 |
Family
ID=27558195
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003535542A Pending JP2005506340A (ja) | 2001-10-16 | 2002-10-16 | 血液脳関門をわたる過小グリコシル化タンパク質の標的化のための方法および組成物 |
| JP2009143436A Pending JP2009203241A (ja) | 2001-10-16 | 2009-06-16 | 血液脳関門をわたる過小グリコシル化タンパク質の標的化のための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009143436A Pending JP2009203241A (ja) | 2001-10-16 | 2009-06-16 | 血液脳関門をわたる過小グリコシル化タンパク質の標的化のための方法および組成物 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1446007A4 (enExample) |
| JP (2) | JP2005506340A (enExample) |
| AU (3) | AU2002347910A1 (enExample) |
| CA (1) | CA2463473A1 (enExample) |
| IL (1) | IL161352A0 (enExample) |
| WO (2) | WO2003032913A2 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| WO2002087510A2 (en) | 2001-04-30 | 2002-11-07 | Symbiontics, Inc. | Subcellular targeting of therapeutic proteins |
| AU2002347910A1 (en) * | 2001-10-16 | 2003-04-28 | Symbiontics Inc. | Methods and compositions for targeting proteins across the blood brain barrier |
| US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| EP1514106A4 (en) * | 2002-05-29 | 2007-05-09 | Zystor Therapeutics Inc | TARGETED THERAPEUTIC PROTEINS |
| CA2553955C (en) * | 2004-02-10 | 2012-08-28 | Zystor Therapeutics, Inc. | Acid alpha-glucosidase and fragments thereof |
| AU2008282496B2 (en) | 2007-07-27 | 2013-04-04 | Armagen Technologies, Inc. | Methods and compositions for increasing alpha-iduronidase activity in the CNS |
| BRPI0820819B1 (pt) * | 2007-12-21 | 2021-06-08 | F. Hoffmann-La Roche Ag | formulação de anticorpos humanizados b-ly 1 e seu uso |
| JP5627571B2 (ja) | 2008-05-07 | 2014-11-19 | バイオマリン ファーマシューティカル インコーポレイテッド | リソソーム標的化ペプチドおよびその使用 |
| EP3679942A1 (en) | 2009-06-17 | 2020-07-15 | BioMarin Pharmaceutical Inc. | Formulations for lysosomal enzymes |
| EP2485761B1 (en) | 2009-10-09 | 2019-02-27 | Armagen, Inc. | Methods and compositions for increasing iduronate 2-sulfatase activity in the cns |
| JP6073783B2 (ja) | 2010-06-25 | 2017-02-01 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | ヘパランｎ−スルファターゼのｃｎｓ送達のための方法および組成物 |
| AU2011270672B2 (en) * | 2010-06-25 | 2017-01-12 | Shire Human Genetic Therapies, Inc. | Treatment of Sanfilippo Syndrome type B |
| LT2588130T (lt) | 2010-06-25 | 2016-12-12 | Shire Human Genetic Therapies, Inc. | Terapinės priemonės pristatymas cns |
| PT3103469T (pt) | 2010-06-25 | 2021-03-04 | Shire Human Genetic Therapies | Administração de agentes terapêuticos no snc |
| KR20230159646A (ko) | 2010-06-25 | 2023-11-21 | 샤이어 휴먼 지네틱 테라피즈 인크. | 이듀로네이트-2-설파타제의 cns 전달을 위한 방법들 및 조성물들 |
| HRP20191923T1 (hr) | 2010-06-25 | 2020-01-10 | Shire Human Genetic Therapies, Inc. | Postupci i sastavi za isporuku arilsulfataze a u cns |
| CN104145015A (zh) * | 2011-12-01 | 2014-11-12 | 安吉奥开米公司 | 靶向的溶酶体酶化合物 |
| US20140377244A1 (en) | 2011-12-23 | 2014-12-25 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
| JP2015526434A (ja) | 2012-08-14 | 2015-09-10 | アンジオケム インコーポレーテッド | ペプチド−デンドリマーコンジュゲート及びその使用 |
| ES2729997T3 (es) | 2012-11-27 | 2019-11-07 | Biomarin Pharm Inc | Proteínas de fusión terapéuticas dirigidas de enzima lisosómica y usos de las mismas |
| AU2014229282B2 (en) * | 2013-03-15 | 2017-02-02 | Glaxosmithkline Intellectual Property (No.2) Limited | Low concentration antibody formulations |
| SI2970413T1 (sl) | 2014-04-01 | 2018-10-30 | Swedish Orphan Biovitrum Ab (Publ) | Modificirana sulfamidaza in proizvodja le-te |
| EP3307326B9 (en) | 2015-06-15 | 2021-02-24 | Angiochem Inc. | Methods for the treatment of leptomeningeal carcinomatosis |
| MX2018010196A (es) | 2016-02-24 | 2018-11-19 | Biomarin Pharm Inc | Proteinas de fusion de enzimas lisosomales terapeuticas dirigidas, formulaciones asociadas y usos de las mismas. |
| BR112020021962A2 (pt) * | 2018-04-30 | 2021-01-26 | Amicus Therapeutics, Inc. | construtos para terapia gênica e métodos de uso |
| CN113631182B (zh) | 2018-10-10 | 2025-03-21 | 阿米库斯治疗学公司 | 二硫键稳定的多肽组合物和使用方法 |
| US20220002688A1 (en) | 2018-12-20 | 2022-01-06 | Armagen, Inc. | Purification of iduronate-2-sulfatase immunoglobulin fusion protein |
| EP4291246A4 (en) * | 2021-02-11 | 2024-12-11 | Denali Therapeutics Inc. | ANTI-TRANSFERRIN RECEPTOR FUSION PROTEINS AND METHODS OF USE THEREOF |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4801575A (en) * | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US5672683A (en) * | 1989-09-07 | 1997-09-30 | Alkermes, Inc. | Transferrin neuropharmaceutical agent fusion protein |
| WO1991004014A1 (en) * | 1989-09-21 | 1991-04-04 | Synergen, Inc. | Method for transporting compositions across the blood brain barrier |
| US6472140B1 (en) * | 1997-09-05 | 2002-10-29 | The General Hospital Corporation | α-2- macroglobulin therapies and drug screening methods for Alzheimer's disease. |
| WO2002087510A2 (en) * | 2001-04-30 | 2002-11-07 | Symbiontics, Inc. | Subcellular targeting of therapeutic proteins |
| AU2002347910A1 (en) * | 2001-10-16 | 2003-04-28 | Symbiontics Inc. | Methods and compositions for targeting proteins across the blood brain barrier |
| EP1514106A4 (en) * | 2002-05-29 | 2007-05-09 | Zystor Therapeutics Inc | TARGETED THERAPEUTIC PROTEINS |
-
2002
- 2002-10-16 AU AU2002347910A patent/AU2002347910A1/en not_active Abandoned
- 2002-10-16 IL IL16135202A patent/IL161352A0/xx unknown
- 2002-10-16 EP EP02801739A patent/EP1446007A4/en not_active Withdrawn
- 2002-10-16 JP JP2003535542A patent/JP2005506340A/ja active Pending
- 2002-10-16 WO PCT/US2002/032996 patent/WO2003032913A2/en not_active Ceased
- 2002-10-16 WO PCT/US2002/032968 patent/WO2003032727A1/en not_active Ceased
- 2002-10-16 CA CA002463473A patent/CA2463473A1/en not_active Abandoned
- 2002-10-16 AU AU2002362930A patent/AU2002362930A2/en not_active Abandoned
-
2009
- 2009-06-16 JP JP2009143436A patent/JP2009203241A/ja active Pending
-
2010
- 2010-08-25 AU AU2010214643A patent/AU2010214643A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005506340A5 (enExample) | ||
| WO2002043746A3 (en) | Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension | |
| JPH09504177A (ja) | Ｐｔｈ活性を有する化合物およびこれをコードする組み換えｄｎａベクター | |
| ES2327986T3 (es) | Liberacion intranuclear de compuestos dirigida por la proteina de choque termico de 70 kd. | |
| JPH02504279A (ja) | インスリン様成長因子１（ｉｇｆ‐１）または因子２（ｉｇｆ‐２）の類縁ペプチド | |
| DE602004024041D1 (de) | Lösliches hyaluronidase-glycoprotein (shasegp), verfahren zu seiner herstellung, verwendungen und dieses enthaltende pharmazeutische zusammensetzungen | |
| JP2008526749A5 (enExample) | ||
| BG105461A (en) | Modified peptides as therapeutic agents | |
| AU2025271034A1 (en) | Engineered hemichannels, engineered vesicles, and uses thereof | |
| WO1994023751A1 (de) | Nukleinsäure-transferpeptide und deren verwendung zur einschleusung von nukleinsäuren in eukaryontische zellen | |
| AU665046B2 (en) | Molecules for iontophoretic delivery | |
| EP3565573B1 (en) | Pac1 receptor agonists (maxcaps) and uses thereof | |
| ZA200602000B (en) | Albumin-binding derivatives of therapeutic peptides | |
| RU2002130203A (ru) | Пептидные конъюгаты для доставки лекарственного средства | |
| CN1879888B (zh) | 透皮给药增强剂及其使用方法 | |
| US5843887A (en) | Compositions for delivery of polypeptides, and methods | |
| BR112020026267A2 (pt) | Lisinas e seus derivados resensibilizam novamente staphylococcus aureus e bactérias gram-positivas aos antibióticos | |
| CA2311648A1 (en) | Ifnar2/ifn complex | |
| WO1998037100A3 (en) | Therapeutic use of the smr1 protein and active derivatives thereof | |
| F Nahhas et al. | Nanoscale pathogens treated with nanomaterial-like peptides: a platform technology appropriate for future pandemics | |
| JP2007506713A (ja) | 例えば、抗血管新生活性を有するペプチドおよび治療におけるその適用 | |
| WO2002058589A3 (en) | Agents and methods for promoting bone growth | |
| AU681891B2 (en) | Medical use of stem bromelain protease | |
| US20250257105A1 (en) | Icam-1 targeted fusion enzymes | |
| WO1999002120A3 (en) | Compositions and methods for reversibly increasing permeability of biomembranes |